Multiple Sclerosis Drugs - Lithuania

Lithuania

The Multiple Sclerosis Drugs market in Lithuania is projected to reach a revenue of US$7.05m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.30%, leading to a market volume of US$7.52m by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue, amounting to US$11,770.00m in 2024.
Lithuania is experiencing a growing demand for innovative Multiple Sclerosis drugs, as the country's healthcare system focuses on improving treatment options for patients.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Lithuania is a developing market with increasing demand for drugs.

Customer preferences: Patients in Lithuania prefer using oral drugs instead of injectable drugs due to the convenience and ease of use. The preference for oral drugs is a global trend, and it is reflected in Lithuania as well. Patients also prefer drugs with fewer side effects and better efficacy.

Trends in the market: The Multiple Sclerosis Drugs market in Lithuania is growing due to the increasing prevalence of multiple sclerosis in the country. The market is also driven by the introduction of new drugs with better efficacy and fewer side effects. The market is dominated by a few major players who have a strong presence in the country.

Local special circumstances: The healthcare system in Lithuania is publicly funded, and the government plays a significant role in regulating the pharmaceutical industry. The government has implemented policies to promote the use of generic drugs to reduce healthcare costs. The policies have led to an increase in the use of generic drugs in the country, including generic drugs for multiple sclerosis.

Underlying macroeconomic factors: Lithuania has a growing economy, and the healthcare sector is one of the fastest-growing sectors in the country. The government has increased healthcare spending in recent years, which has led to an increase in the availability of drugs in the country. The aging population in Lithuania is also driving the demand for drugs for multiple sclerosis, as the disease is more prevalent in older individuals. Overall, the Multiple Sclerosis Drugs market in Lithuania is expected to grow in the coming years due to the increasing prevalence of the disease and the introduction of new drugs with better efficacy and fewer side effects.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.